Category Archives: Cannabis Legalization

NBA stars John Wall, Carmelo Anthony invest in cannabis company LEUNE

National Basketball Association stars John Wall and Carmelo Anthony are new investors in a cannabis company.

The pair helped California-based LEUNE raise roughly $5 million in a round that includes NBA agent Rich Paul, entertainer La La Anthony, music manager Anthony Saleh (clients include Future and Nas) and venture capital firm Casa Verde Capital.

 

LEUNE said it would use the funds for marketing and expanding its products as it looks to capitalize on more states legalizing marijuana.

To read more:

Canopy Growth Makes Major Canadian Acquisition

Canopy Growth Makes Major Canadian Acquisition

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) and The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) are pleased to announce that they have entered into a definitive arrangement agreemen under which Canopy will acquire all of Supreme Cannabis’ issued and outstanding common shares (the “Supreme Cannabis Shares”) in a transaction valued at approximately $435 million on a fully-diluted basis (the “Transaction”).

Canopy Growth has announced a definitive agreement to acquire The Supreme Cannabis Company. (CNW Group/Canopy Growth Corporation)

Under the terms of the Arrangement Agreement, Supreme Cannabis shareholders will receive 0.01165872 of a Canopy common share (the “Exchange Ratio”) and$0.0001 in cash in exchange for each Supreme Cannabis Share held. The Transaction provides Supreme Cannabis shareholders with a premium per Supreme Cannabis Share of approximately 66% based on the closing prices of the Supreme Cannabis Shares and Canopy common shares on the Toronto Stock Exchange (the “TSX”) as of April 7, 2021 .

The Transaction is expected to provide several benefits to both Canopy and Supreme Cannabis shareholders. Notably, following completion of the acquisition, Canopy will possess a strengthened brand portfolio including one of Canada’s leading premium brands, 7ACRES. Brand growth is anticipated with distribution supported by Canopy’s robust sales and distribution network as well as superior consumer insights and R&D capabilities. In addition to receiving a market premium, Supreme Cannabis shareholders will also benefit from Canopy’s US CBD business and conditional positioning for continued exposure to the US market expansion. Further value will be derived through the scalable Kincardine, Ontario production facility, which has a demonstrated record of producing premium flower at low cost.

Key Transaction Highlights

  • Solidifies Canopy’s leadership position in the Canadian recreational market, well-positioned for growth: The Transaction combines Canopy’s preeminent position with Supreme Cannabis’ Top-10 position in Canada to create a pro forma Canadian recreational market share of 13.6% (1) , including 7ACRES holding Canada’s number one premium flower brand position, number one in PAX vapes, and Top-5 in pre-rolled joints (2) .
    • Combined pro forma market share estimated to be 23.3% of the premium flower segment in Ontario and 21.4% in British Columbia (3) .
  • Adds premium brands to Canopy’s portfolio: The addition of Supreme Cannabis’ premium brands, 7ACRES and 7ACRES Craft Collective, complement Canopy’s current consumer offering and will strengthen Canopy’s brand portfolio, with both brands expected to continue to grow with further investment and expansion. Supreme Cannabis’ Blissco and Truverra brands also add breadth to Canopy’s market presence in both the recreational and medical markets.
  • Brings a premium, low-cost and scalable cultivation facility to Canopy’s production capabilities: Supreme Cannabis’ hybrid-greenhouse cultivation facility at Kincardine, Ontario has a demonstrated capability of consistently producing premium flower from sought-after strains at low cost with significant potential for scaling.
  • Secures an immediate attractive premium for Supreme Cannabis shareholders: The Transaction provides Supreme Cannabis shareholders with a premium per Supreme Cannabis Share of approximately 66% based on the closing prices of the Supreme Cannabis Shares and Canopy common shares on the TSX as of April 7, 2021 .
  • Participation by Supreme Cannabis shareholders in the future of Canopy: The Supreme Cannabis shareholders will receive Canopy common shares pursuant to the Transaction and will have access to Canopy’s consumer insights, advanced R&D and innovation capabilities as well as the opportunity to participate in the future growth of the US market based on the Company’s conditional positioning for rapid market entry. Post-Transaction, Canopy’s industry-leading balance sheet and cash position of approximately $2.5 billion positions the company for further expansion and product development.
  • Opportunity to achieve potential cost synergies estimated at approximately $30mm within two-years: Canopy anticipates post-Transaction cost synergy opportunities across both cost of goods sold and sales, general and administrative expenses, as it optimizes and integrates Supreme’s operations and shared services.

“As we continue to expand our leading brand portfolio, we’re excited to reach more consumers through Supreme’s premium brands and high-quality products, further solidifying Canopy’s market leadership,” said David Klein , Chief Executive Officer of Canopy. “Supreme’s deep commitment to superior genetics, top-tiercultivation and strict quality control, paired with Canopy’s leading consumer insights, advanced R&D and innovation capabilities, is expected to create a powerful combination that aligns with our strategic focus to generate growth with premium quality products across key categories.”

“This transaction is a testament to the value created by all the teams at Supreme and will be beneficial to all of our stakeholders,” added Beena Goldenberg , President and CEO of Supreme Cannabis. “We have been successful at delivering great products that achieved strong customer loyalty, and operating at levels of efficiency that are industry-leading. We have also built a highly sought-after premium brand in 7ACRES. Combining Supreme Cannabis with Canopy – a Canadian market leader with exposure to the United States – presents a significant value creation opportunity for both companies. We look forward to working with Canopy to complete this transaction.”

Transaction Details
The Transaction will be effected by way of a court-approved plan of arrangement under the Canada Business Corporations Act , requiring the approval of at least two-thirds of the votes cast by the shareholders of Supreme Cannabis voting at a special meeting of shareholders to consider the Transaction expected to be held inJune 2021 . Canopy has entered into voting support agreements with certain of Supreme Cannabis’ directors and officers pursuant to which they have agreed, among other things, to vote their Supreme Cannabis Shares in favour of the Transaction.

In addition to shareholder and court approvals, the Transaction is subject to applicable regulatory approvals including, but not limited to, TSX approval and approval under the Competition Act ( Canada ) and the satisfaction of certain other closing conditions customary in transactions of this nature. The Arrangement Agreement includes customary provisions, including non-solicitation, “fiduciary out” and “right to match” provisions as well as a termination fee of $12.5 million payable by Supreme Cannabis to Canopy in certain specified circumstances.

Assuming timely receipt of all necessary court, shareholder, regulatory and other third-party approvals and the satisfaction of all other conditions, closing of the Transaction is expected to occur by end of June 2021 .

A full description of the Transaction will be set forth in the management information circular of Supreme Cannabis (the “Circular”), which will be mailed to Supreme Cannabis shareholders and filed with the Canadian securities regulators on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com .

Approvals and Recommendation
The Transaction was approved by the board of directors of each of Canopy and Supreme Cannabis, and Supreme Cannabis’ board of directors recommends that Supreme Cannabis shareholders vote in favour of the Transaction.

Each of BMO Capital Markets and Hyperion Capital provided the Supreme Cannabis Board of Directors with an opinion, dated April 7, 2021 , to the effect that, as of the date of such opinion, the consideration payable pursuant to the Transaction is fair, from a financial point of view, to the Supreme Cannabis shareholders, in each case, based upon and subject to the respective assumptions, limitations, qualifications and other matters set forth in such opinions.

None of the securities to be issued pursuant to the Transaction have been or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and any securities issuable in the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Advisors and Counsel
Cassels Brock & Blackwell LLP is acting as strategic and legal advisor to Canopy.

BMO Capital Markets is acting as exclusive financial advisor to Supreme Cannabis and provided a fairness opinion to the Supreme Cannabis board of directors. Hyperion Capital Inc. provided an independent fairness opinion to the board of directors of Supreme Cannabis. Borden Ladner Gervais LLP is acting as legal counsel to Supreme Cannabis.

(1)

Source: Provincial Boards; Headset Note: This market share data differs from Canopy’s internal market share data provided during Canopy’s previous earnings calls due to different methodologies and time periods. Market share data represents 01-Oct-20 through latest available data: Provincial Board data for ON online, PEI, NS (27/28-Mar-21) and NB (17-Mar-21); and Headset data for ON retail (28-Feb-21) and AB, BC and SK (31-Mar-21).

(2)

Market share data represents 01-Oct-20 through latest available data: Provincial Board data for ON online, PEI, NS (27/28-Mar-21) and NB (17-Mar-21); and Headset data for ON retail (28-Feb-21) and AB, BC and SK (31-Mar-21).

(3)

Internal Canopy Growth management estimate.

About Canopy Growth
Canopy Growth (TSX:WEED, NASDAQ:CGC) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high-quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany . Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada , the United States , and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally-permissible CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information visit www.canopygrowth.com .

About Supreme Cannabis
The Supreme Cannabis Company, Inc. , (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), is a global diversified portfolio of distinct cannabis companies, products and brands. Since 2014, the Company has emerged as one of the world’s most premium producers of recreational, wholesale and medical cannabis products.

Supreme Cannabis’ portfolio of brands caters to diverse consumer and patient experiences, with brands and products that address recreational, wellness, medical and new consumer preferences. The Company’s recreational brand portfolio includes, 7ACRES , 7ACRES Craft Collective , Blissco , sugarleaf , and Hiway . Supreme Cannabis addresses national and international medical cannabis opportunities through its premium Truverra brand.

Supreme Cannabis’ brands are backed by a focused suite of world-class operating assets that serve key functions in the value chain, including, scaled cultivation, value-add processing, automated packaging and product testing and R&D. Follow the Company on Instagram , Twitter , Facebook , LinkedIn and YouTube .

We simply grow better.

Notice Regarding Forward-Looking Information
This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Canopy, Supreme Cannabis or their respective subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to the timing and outcome of the Arrangement, the anticipated benefits of the Transaction, the estimated potential synergies as a result of the Transaction, the anticipated timing of the Supreme Cannabis special meeting of shareholders and the closing of the Transaction, the satisfaction or waiver of the closing conditions set out in the Arrangement Agreement, including receipt of all regulatory approvals. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including assumptions as to the time required to prepare and mail meeting materials to Supreme Cannabis shareholders; the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholder approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the Transaction; the prompt and effective integration of Canopy’s and Supreme’s businesses and the ability to achieve the anticipated synergies contemplated by the Transaction; inherent uncertainty associated with financial or other projections; risks related to the value of the Canopy common shares to be issued pursuant to the Transaction; the diversion of management time on Transaction-related issues; expectations regarding future investment, growth and expansion of Canopy’s and Supreme’s operations; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; risks related to infectious diseases, including the impacts of the Covid-19 pandemic; legal and regulatory risks inherent in the cannabis industry, including the global regulatory landscape and enforcement related to cannabis, political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of Canopy filed with Canadian securities regulators and available under Canopy’s profile on SEDAR at www.sedar.com and with the United States Securities and Exchange Commission through EDGAR at www.sec.gov/edgar , including Canopy’s annual report on Form 10-K for the year ended March 31, 2020 , as amended, and in the public filings of Supreme Cannabis filed with Canadian securities regulators and available under Supreme Cannabis’ profile on SEDAR at www.sedar.com , including Supreme Cannabis’ annual information form for the year ended June 30, 2020 .

In respect of the forward-looking statements and information concerning the anticipated benefits and completion of the Transaction and the anticipated timing for completion of the Transaction, Canopy and Supreme Cannabis have provided such statements and information in reliance on certain assumptions that they believe are reasonable at this time. Although Canopy and Supreme Cannabis believe that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy and Supreme Cannabis have attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and Canopy and Supreme Cannabis do not undertake any obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Cision

View original content to download multimedia: http://www.prnewswire.com/news-releases/canopy-growth-to-acquire-the-supreme-cannabis-company-301264708.html

SOURCE Canopy Growth Corporation

 

Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2021/08/c0503.html

Published at Thu, 08 Apr 2021 12:03:00 +0000

HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper

HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper

HempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) (FWB:8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce it has completed, in collaboration with the Inflammatory Markers Laboratory (“IML”) located in Wichita, Kansas, a pilot study that assessed the effect of the HempFusion formulation CBD Capsules® (HempFusion 20mg CBD capsules with botanical terpenes) as it relates to a combination of anti-inflammatories in lowering the results of the chronic inflammation test (which measures urinary 11-dehydro thromboxane B2, the stable end product of intracellular thromboxane metabolism that has been shown to correlate with inflammation) and has released a white paper titled “Oral Formulation May Modulate Thromboxane Production[i].

Results of the pilot study have shown potential promise in the area of inflammatory markers and possible effects on exaggerated inflammation.

“Our laboratory has demonstrated the effectiveness of numerous products in reducing thromboxane production,” commented Gordon Ens, Director of IML. “I was pleased to see a CBD product show such a significant reduction of thromboxane in this pilot trial.”

The white paper, expected to be published shortly, is co-authored by Gordon Ens, Director of IML and George Fritsma, Professor at University of Alabama, and illustrates the potential of tracking and elucidating biomarkers sensitive to inflammation in addition to how novel compounds and formulas modulate the expression of these markers.

Jason Mitchell, N.D., HempFusion’s Co-Founder and Chief Executive Officer commented, “We are committed to furthering research in the area of hemp-derived CBD and this pilot trial and soon to be published white paper reinforces our continued focus on the safe and effective use of hemp-derived CBD products.”

HempFusion is dedicated to research related to toxicology safety, which is evident through its involvement and co-sponsoring of the ValidCare Human Observational Safety Study, what is believed to be the largest CBD toxicology study of its kind ever completed to date. HempFusion continues to focus on research & development, pilot studies, and clinical trials, to advance the science of CBD.

ABOUT HEMPFUSION

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com.

Follow HempFusion on TwitterFacebook and Instagram and Probulin on TwitterFacebook and Instagram.

CONTACT INFORMATION

Jason Mitchell, N.D.
Chief Executive Officer and Director
Email: ir@hempfusion.com
Phone: 416-803-5638

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements“) that relate to HempFusion’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements relating to the publication of the white paper and the Company’s plans, focus and objectives.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond HempFusion’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under “Forward-Looking Statements” and “Risk Factors” in the final long form prospectus of the Company dated December 17, 2020 and available under the Company’s profile on SEDAR at www.sedar.com. HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for HempFusion to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Thu, 25 Mar 2021 11:42:36 +0000

Technical420 Deep Dive: There Is Still A Ton Of Value For Investors To Extract From The Cannabis Oil Trade

Technical420 Deep Dive: There Is Still A Ton Of Value For Investors To Extract From The Cannabis Oil Trade

During the last year, the cannabis industry has recorded impressive growth as new markets open across the globe. 

The opening of new markets has led to an increase in the number of export agreements, and this has greatly benefitted Canadian cannabis companies. One of the most attractive aspects of this trend is related to the amount of cannabis concentrates that are being sent to emerging international markets. 

The trend toward cannabis oil represents a shift from previous export agreements that primarily involved cannabis flower and we expect the shift to continue to trend toward cannabis oil. Prior to the legalization of cannabis derivative products in Canada (referred to as cannabis 2.0), several companies put a major emphasis on the cannabis oil markets and constructed facilities that met European Union good manufacturing practices (EU GMP) standards. 

Going forward, we expect to see consumers show a preference for products that are made from cannabis oil such as edibles, vape pens, beverages, concentrates, shatters, topicals, and more. Today, we want to highlight 5 companies that are highly focused on the cannabis oil market and believe our readers need to be aware of these operators. 

MediPharm Labs is a Misunderstood Cannabis Oil Operator

Earlier this year, we highlighted MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) as one of the most attractive Canadian cannabis oil companies. Our view on the company is based on the growth of the business in Canada and abroad, its valuation, and the potential catalysts it has for growth. 

From legal cannabis markets to the pharmaceutical sector, we believe that MediPharm represents a differentiated growth opportunity and is trading at a discount when compared to its peers. We are of the opinion that the pharmaceutical industry represents a significant opportunity for MediPharm and are favorable on how this aspect of the story has advanced. 

In January, MediPharm reported a record number of shipments of finished goods in the fourth quarter. During the quarter, the company shipped 550,000 units, and we are impressed with how the business has bounced back. When compared to the prior quarter, MediPharm reported a more than 200% increase in the number of units that were shipped. 

The number of units that were shipped does not include any international sales which we believe is an attractive vertical of the business. From Australia to South America, MediPharm has been laser focused on the international cannabis concentrate market and we consider the business to be a leader in this vertical. In the back half of the year, we expect the company to report increasing revenue growth from international markets.

Since inception, MediPharm has been focused on using state-of-the-art equipment to develop premium concentrates for businesses and consumers. As a result of the continued execution, the company has created a reputation for quality and purity, and we believe this trend supports the growth of the entire business.

During the fourth quarter, MediPharm entered into a supply agreement with Nova Scotia Liquor Corporation. The company has retail distribution agreements with six provinces (B.C., Alberta, Saskatchewan, Manitoba, Ontario and Nova Scotia) and we are bullish on the growth prospects that are associated with the domestic business.

Earlier this year, MediPharm Labs announced an important milestone and was issued a Cannabis Drug License (CDL) from Health Canada. The license is necessary for the company to manufacture and supply cannabis-based drugs. The products that are allowed with a CDL include pharmaceutical prescription drugs that have a drug identification number (DIN).

In the near-term, MediPharm is well positioned to supply cannabis based pharmaceutical drugs and active pharmaceutical ingredients (APIs) to other CDL license holders and clinical research trials for novel drug discovery. We believe the market is discounting the impact that this initiative will have on the business and find the risk-reward profile to be favorable.

Going forward, the opportunity for MediPharm with its existing pharmaceutical customers to produce existing approved cannabis drugs or to develop and manufacture new and innovative drugs through later stage clinical trials is significant. Currently, there are thousands of active cannabis focused clinical trials taking place and we expect the CDL to serve as a substantial growth driver for the business over the long-term.

We believe that MediPharm Labs is an execution story that is trading at a considerable discount. At current levels, we find the valuation to be attractive on several metrics and believe that MediPharm has a favorable risk-reward profile. Going forward, we expect the company to announce strong growth and will monitor how the story advances from here.

Aleafia Health has Been Executing on the Cannabis 2.0 Market 

Aleafia Health Inc. (AH.TO) (ALEAF) is a Canadian cannabis producer that has been highly focused on the cannabis oil market. Based on the infrastructure and facilities that are operational, the company has 50,000 kilograms of extraction capacity and is well positioned to capitalize on the cannabis oil market. We are bullish on the amount of revenue that can be generated through the company’s facilities as well as through the distribution that is already in place.

Last year, Aleafia Health became highly focused on the cannabis 2.0 opportunity and owns a diverse cannabis product portfolio that is comprised of high-margin derivative products (i.e. oils, capsules, and sprays). The portfolio has been further developed through a recent expansion to vape cartridges, sublingual strips, and ultra-high-potency CBD oil. We are favorable on the approach that Aleafia Health’s management team has employed to execute on the cannabis 2.0 market and expect this vertical to record strong growth in 2021.

In November, Aleafia Health brought its first cannabis 2.0 product to Canada’s recreational market and this is a trend that has since become more significant. The company entered the market with the launch of a vape cartridge and we are bullish on how the product has been gaining traction on the medical and recreational sides of the business.

One of the reasons why Aleafia Health is well positioned to record substantial growth is due to the amount of 2.0 products that can be created with cannabis from an outdoor operation. There is a huge difference in the quality and type of cannabis that is grown in an indoor facility and that in an outdoor facility. By using the cannabis from the outdoor operation to create derivative products, the consumer might not be able to identify the source of the cannabis that the products are derived from but will certainly recognize the quality.

Aleafia Health is executing on a multi-faceted growth strategy that is focused on ramping revenues, cutting costs, and seeing margin expansion. When it comes to the cannabis 2.0 market we are favorable on how this aspect of the business has advanced. One of the products the company sells is a US brand called Kin Slips, which utilizes a sublingual strip delivery method. This is a unique product, and we are favorable with the rapid onset time that is associated with it. Through relationships like this, Aleafia Health has been able to differentiate itself from its peers and we are favorable on how this has positioned the business for growth.

Aleafia Health is working on the production of its first edible confection product in the form of soft candies. The products were formulated and produced at the Paris Facility and should launch in the near future. We expect to see strong demand for these edible products and expect the launch to serve as a catalyst for growth.

Over the next year, Aleafia Health expects to release several new cannabis derivative products and we are favorable on the amount of revenue that can be generated by these products. Since inception, the company has focused on forming relationships with leading US cannabis brands and selling these products in Canada.

HEXO Corp. Is Out To Be The North American Beverage Leader

During the last year, HEXO Corporation (HEXO.TO) (HEXO) has become much more focused on the cannabis oil market and we attribute this to the relationship that it has with Molson Coors Inc. (TAP). The relationship is focused on developing and commercializing cannabis beverages and it needs access to a lot of cannabis oil to execute on this vertical. 

HEXO is focused on the production of CBD and THC cannabis oil and is executing on a multi-national growth strategy with Molson Coors. Initially, the cannabis beverage partnership will focus on selling CBD infused beverages in the US and THC infused beverage in Canada. The companies plan to start selling THC beverages in the US once the Federal government changes its stance on the legalization or decriminalization of cannabis. 

Going forward, we expect HEXO and Molson continue to need large quantities to execute on the cannabis beverage vertical. We expect the Canadian cannabis company to also need cannabis oil to develop and sell additional cannabis 2.0 products like edibles, vape pens, concentrates, and more. 

In 2020 we noticed a significant change in investor sentiment with HEXO and believe that the Molson Coors relationship played an important role in this. We consider the Canadian cannabis producer to be a turnaround story in the making and expect Canada’s cannabis 2.0 market to play a crucial role in this. 

What Will WeedMD Do With CX Industries?

A few years ago, we visited WeedMD’s (WMD.V) (WDDMF) state-of-the-art cultivation facility in Aylmer, Canada and were impressed with the structure of the operation. Shortly after our visit, the Canadian cannabis company announced that it would put a major focus on the cannabis oil market and formed CX Industries Inc. to do so. 

CX Industries specializes in extraction, toll processing and third-party product formulation from its fully licensed facility in Aylmer. Last year, the company announced that CX plans to process more than 50,000 kilograms of biomass per year (when it is operating at peak production). When we first learned about the launch of the division, we were favorable on the plan for the business unit to capitalize on a burgeoning market ahead of the legalization of cannabis 2.0 products in Canada. 

Last year, WeedMD issued an update on CX and reported that it is offering tolling and white labelling services to other Canadian cannabis producers and brands. Last year, two Vitalis Q90 extractors at CX Industries were installed to commercialize products and we are waiting to learn more about this division of the business. 

During the last year, WeedMD has been under considerable pressure and the market seems to have lost faith in it. The company has been negatively impacted by a change in management team, less than optimal performance by the outdoor facility, and more limited access to equity capital. We are cautiously optimistic with WeedMD and will monitor how the story evolves from here. 

Aphria and Tilray are Positioned to be a Market Leader

In late 2020, Tilray Inc. (TLRY) shocked the market when it announced a merger agreement with Aphria Inc. (APHA.TO) (APHA). The combined company would be well positioned to capitalize on the global cannabis market and will be one of the largest producers of cannabis oil. 

The combined company would be expected to take a leadership position in Canada and we are bullish on the potential synergies that could be found between the operators. Aphria has been highly focused on the Canadian and the international cannabis opportunities and we are favorable on the amount of distribution that it has in the EU.

As it relates to the cannabis derivative product market, both Aphria and Tilray represent attractive opportunities. Prior to the merger announcement, Aphria acquired Sweetwater Brewing Company and we are favorable on how the asset positions the business to capitalize on the US market. 

To make cannabis beverages, a company needs to have access to cannabis oil and we are favorable on how the combined company will be positioned to capitalize on this vertical. Going forward, we expect the combined company to start selling cannabidiol (CBD) beverages in the US and are favorable on the direction the business is heading. 

Since inception, Tilray has been highly focused on the Canadian medical cannabis market and strategic international markets. Many of the products that will be sold by the combined company will be created with cannabis oil and we will monitor how the story advances this year. 

Share

Share - Facebook


Share - Twitter

Published at Tue, 23 Mar 2021 11:37:04 +0000

Canopy Growth Announces US$750 Million Term Loan Financing

Canopy Growth Announces US$750 Million Term Loan Financing

Canopy Growth Corporation (“Canopy Growth” or “Canopy” or the “Company”) (TSX: WEED) (NASDAQ: CGC) is pleased to announce that it has entered into a credit agreement (the “Credit Agreement”)  with Funds advised by King Street Capital Management, L.P. (“King Street”). Under the Credit Agreement, the Company has raised a US$750 million senior secured term loan (the “Term Loan Facility”). The Company also has the ability to obtain up to an additional US$500 million of incremental senior secured debt pursuant to the Credit Agreement.

Logo: Canopy Growth Corporation (CNW Group/Canopy Growth Corporation)

“We are delighted to welcome King Street as our anchor debt investor and look forward to building value for both our credit and equity investors over time,” said Mike Lee , EVP and CFO of Canopy Growth. “This transaction further strengthens Canopy’s balance sheet, provides additional capital to invest in high-return growth opportunities, and marks a key milestone for us as we work towards achieving a more efficient capital structure”.

“We have been impressed with the growth of Canopy as a leader in the Canadian market and look forward to providing this strategic capital as Canopy further expands its business,” said Noah Charney , Managing Director at King Street.

The Term Loan Facility has no amortization payments and matures on March 18, 2026 . The gross proceeds, net of fees and expenses, will be used by Canopy Growth for working capital and general corporate purposes, including without limitation, growth investments, acquisitions, capital expenditures, and strategic initiatives. The Term Loan Facility has a coupon of LIBOR plus 8.50% and is subject to a LIBOR floor of 1.00%. Giving effect to the net proceeds from the Term Loan Facility, the Company’s estimated pro forma cash, cash equivalents and short-term investments position as at December 31, 2020 would have been approximately CAD$2.5 billion .

Greenhill & Co. acted as financial advisor to Canopy Growth. Cassels Brock & Blackwell LLP acted as Canadian counsel to Canopy Growth, and Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as US counsel to Canopy Growth. Goodmans LLP acted as Canadian counsel and Davis Polk & Wardwell LLP acted as US counsel to King Street.

About Canopy Growth

Canopy Growth (TSX: WEED , NASDAQ:CGC) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States , and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally-permissible CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information visit www.canopygrowth.com .

About King Street

King Street is an $18 billion global investment management firm founded in 1995 with offices in New York , London , Singapore , Tokyo andCharlottesville, VA . King Street employs a fundamental, research-intensive approach across multiple strategies, markets, industries and asset classes including an expanding lending platform.

Notice Regarding Forward Looking Statements

This press release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable U.S. and Canadian securities laws (collectively, “forward-looking statements”), which involve certain known and unknown risks and uncertainties. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use of such terms and phrases as “intend,” “goal,” “strategy,” “estimate,” “expect,” “project,” “projections,” “forecasts,” “plans,” “seeks,” “anticipates,” “potential,” “proposed,” “will,” “should,” “could,” “would,” “may,” “likely,” “designed to,” “foreseeable future,” “believe,” “scheduled” and other similar expressions. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Forward–looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those forward–looking statements and the forward-looking statements are not guarantees of future performance. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. A discussion of some of the material factors applicable to the Company can be found under the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020, filed with the Securities and Exchange Commission and with applicable Canadian securities regulators, as such factors may be further updated from time to time in its periodic filings with the Securities and Exchange Commission and with applicable Canadian securities regulators, which can be accessed at www.sec.gov/edgar and www.sedar.com , respectively. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in the filings. Any forward–looking statement included in this press release is made as of the date of this press release and, except as required by law, the Company disclaims any obligation to update or revise any forward-looking statement. Readers are cautioned not to put undue reliance on any forward-looking statement. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement

Cision

View original content to download multimedia: http://www.prnewswire.com/news-releases/canopy-growth-announces-us750-million-term-loan-financing-301250141.html

SOURCE Canopy Growth Corporation

Published at Thu, 18 Mar 2021 11:39:47 +0000

Aleafia Health Expands Adult-use Presence with Entrance in Saskatchewan, new Provincial Market

Aleafia Health Expands Adult-use Presence with Entrance in Saskatchewan, new Provincial Market

Aleafia Health Inc. (TSX: AH, OTC: ALEAF) is pleased to announce that its products are now available to consumers in Saskatchewan. The initial provincial launch includes a broad array of Aleafia Health’s cannabis product portfolio, including sublingual strips, cannabis oils, dried flower, and vape cartridges. The Company’s adult-use products are now available in four provinces representing 67 per cent of the Canadian population.

“The expansion into this new market is part of a much broader adult-use strategy that we continue to accelerate through the launch of exciting new product formats,” said Aleafia Health CEO Geoffrey Benic. “We are excited to begin expanding our presence in Saskatchewan, a province which boasts a well-earned reputation for a business and consumer-friendly cannabis regulatory regime.”

This follows the launch of Aleafia Health’s Canadian cannabis portfolio Sunday Market. Under the Sunday Market family are four new distinct brands, including the cannabis edibles brand Bogart’s Kitchen, which launched with THC Soft Chews in March 2020.

For Investor & Media Relations:

Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.

Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Tue, 16 Mar 2021 11:52:30 +0000

Icanic Brands Announces Mr. Mark Smith as Executive Chairman

Icanic Brands Announces Mr. Mark Smith as Executive Chairman

Icanic Brands Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“Icanic Brands” or the “Company”), a multi-state brand operator of premium Cannabis brands in California and Nevada, is pleased to announce that effective March 1st, 2021, Mr. Mark Smith has been appointed as the Company’s Executive Chairman.

Mr. Smith brings a wealth of expertise to this role, having founded, built and transacted over $200,000,000 USD in US Cannabis businesses over the past 7 years. His capabilities include extensive industry start-up and scaling experience, strong financial orientation and experience operating in highly regulated markets including Colorado, Nevada and Michigan. Mr. Smith is an experienced and proven Cannabis entrepreneur with a track record of building enduring industry brands while leveraging operational scale. Mr. Smith has been actively involved in developing best-in-class brands such as Cannapunch, Highly Edible, Dutch Girl and Nordic Goddess (all of which were acquired by AYR Wellness Inc. formerly, AYR Strategies Inc. and Cannabis Strategies Acquisition Corp.) as well as developing a chain of dispensaries with his team members (his family) called Tumbleweed.

“What has attracted me to this venture is the talent and energy of the Icanic Brands team, predominately the CEO’s vision to leverage the Ganja Gold family of brands and attract additional acquisition partners. You can’t put a price on human capital and his energy and exuberance has been a missing ingredient in most cannabis companies who are not builders of businesses. We will be builders,” says Mr. Smith.

– ADVERTISEMENT –

In his role as Executive Chairman at Icanic Brands, Mr. Smith will focus his time and energy on expanding the Company’s brand footprint in new states, new product development and expansion of the product line all with the singular goal of increasing financial performance with a laser focus on maximizing cash flow and earnings per share. Mr. Smith is widely regarded and respected in the US Cannabis industry as a thought leader and innovator. His network and relationships across the industry will provide the Company with nearly unrivalled access to new product ideas, innovative brands that leverage manufacturing capability and teams that can execute on them.

“Icanic Brands is a unique and highly exciting growth opportunity as the US heads towards a major shift in federal cannabis laws and legislation. The Company has been able to develop what is now a California legacy brand in Ganja Gold and through investment in automation, is at forefront of dominating and extending the pre-roll space in the country,” said Mr. Smith. “I look forward to working with the team to build on the foundation and accelerate expansion into new territories, brands and product categories. Profitability is challenging and I intend to ensure that Icanic Brands continues to be profitable through the disciplined allocation of capital and introducing truly differentiated and innovative products.”

“I am humbled and excited to have Mark join our team in this leadership capacity. His tenure and acumen in the space is unparalleled. His experience in launching new products, building lasting brands and doing so profitably is going to be immediately impactful in our current environment and positioning in the market,” said Mr. Brandon Kou, CEO and Director of Icanic Brands.

Mr. Mark Smith will be issued 500,000 options at $0.55 and additional milestone-based performance equity and currently owns 2,000,000 shares and is in the process of acquiring additional shares.

About Icanic Brands Company, Inc.

Icanic Brands Company, Inc. is a leading cannabis branded products manufacturer based in California & Nevada, the largest and most competitive cannabis markets in the world. The company’s mission is to make cannabis safe and approachable – that starts with manufacturing high-quality products delivering consistent experiences.

For more information, please visit the company’s website at: www.icaninc.com.

About Ganja Gold

Ganja Gold, Inc., a wholly-owned subsidiary of Icanic Brands Company, Inc. (CSE: ICAN, OTCQB: ICNAF), is the premier brand of infused pre-rolls in the state. Ganja Gold focuses on using only the best available flower and concentrates with state of the art proprietary technology to create connoisseur level pre-rolls unseen in the marketplace. With our flagship Tarantula™, Ganja Gold continues to set the bar in quality and experience.

For more information about Ganja Gold, visit their website at www.ganjagold.com

ICANIC BRANDS COMPANY INC.

Per:“Brandon Kou”
Chief Executive Officer

For further information about Icanic Brands, please contact the Company at:
Email: ir@icaninc.com
Phone: (778)999-4226

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Mon, 01 Mar 2021 12:40:43 +0000

Tilray Inc. Receives Double Downgrades Following A Lackluster Earnings Report

Tilray Inc. Receives Double Downgrades Following A Lackluster Earnings Report

Although Tilray Inc. (TLRY) reported strong fourth quarter financials and recorded a more than 20% increase in revenue when compared to the same period last year, broker-dealers have not responded as favorably as we anticipated.

Following the earnings report, Tilray was downgraded by two broker-dealers and we found this to be worth highlighting. Piper Sandler is one of the broker-dealers that downgraded Tilray and we found the price target increase on Tilray by Piper Sandler to be interesting.

While Benchmark simply cut its rating on Tilray from Buy to Hold, Piper Sandler also lowered its rating Buy to Hold and raised the price target to $26 from $15. We believe that Piper Sandler wanted its price target to be closer to the range that Tilray is trading in and are not overly surprised by the price target hike.

During the quarter, Tilray recorded a $3 million net loss on $56.6 million of revenue. For the entire year, the Canadian cannabis producer had a $10 million net loss on $210 million of revenue.

The primary reason for the increase in quarterly revenue is related to the international medical cannabis market as well as the Canadian recreational market. Tilray recognized a significant decline in the amount of revenue it has generated from hemp and attributed the drop to a shift to private label product with a large customer as well as the impact of COVID-related changes to consumer shopping patterns.

When compared to the prior quarter, Tilray recognized a 10% increase in revenue. The increase was primarily related to the leverage that it has to strategic international medical cannabis markets and the Canadian recreational market. We are bullish on the trend and expect the merger with Aphria (APHA.TO) (APHA) will make the combined company the largest cannabis company in the world.

Tilray is trading higher in the pre-market and this is an opportunity that we are closely following. If you are interested in learning more about Tilray and Aphria, please send an email to support@technical420.com with the subject “Tilray and Aphria” to be added to our distribution list.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Thu, 18 Feb 2021 12:24:54 +0000

Aurora Cannabis Gets Price Targets Slashed After Lackluster Q2 Earnings Release

Aurora Cannabis Gets Price Targets Slashed After Lackluster Q2 Earnings Release

Last week, Aurora Cannabis Inc. (ACB.TO) (ACB) released second quarter financial results and the market responded negatively to the numbers.

Following the earnings report, several leading Canadian and US broker-dealers responded with the following:

  1. ATB Capital Markets raised its price target to $13 from $10.50 (CAD)
  2. MKM Partners changed its rating to Sell from Hold
  3. Canaccord Genuity raised its price target to $14 from $11 (CAD)
  4. Stifel raised its price target to $7.8 from $6.50 (CAD)

During the second quarter, Aurora Cannabis recorded a more than $290 million net loss on $70 million of revenue. The company reported a Adjusted EBITDA loss of $16.8 million and the amount included termination and restructuring costs. Most of the net loss is related to non-cash items and we will monitor how Aurora Cannabis’ numbers move from here.

An important metric to highlight from the second quarter is the adjusted gross margin. During the quarter, Aurora Cannabis recorded a 6% decline in margins when compared to the same period last year. The decrease is the result of a reduction in production levels at Aurora Sky which caused there to be an increase in cash cost of sales due to the under-utilization of capacity at the facility.

For the last year, Aurora Cannabis has talked a lot about rightsizing the operation and closing production facilities across the world. Clearly Aurora Cannabis’ rightsizing process is taking longer than expected and we look forward to the day the management team announces that they have completed the process.

In the near-term, we expect Aurora Cannabis to remain challenged and will monitor how it impacts the performance of the brand. The company recently announced a financing agreement and we believe the resources will be key for enhancing the company’s footprint in strategic markets (Canada, the US, the EU, and Latin America).

As of February 10th,  Aurora Cannabis reported to have approximately $565 million of cash on hand. The company continues to focus on improving operational flexibility and expects this project to be a positive for cash flow. Of the four cultivation facilities that Aurora Cannabis plans to close, three are fully shuttered and we will monitor how the management team continues to execute on this.

During the last month Aurora Cannabis has seen its stock price surge higher and it is currently trading above the price target levels that were reported by broker-dealers (highlighted in the beginning of the story). Going forward, we are cautious with Aurora Cannabis and this is due to the volatility that is associated with the trend.

If you are interested in learning more about Aurora Cannabis, please send an email to support@technical420.com with the subject “Aurora Cannabis” to be added to our distribution list.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Fri, 12 Feb 2021 14:29:37 +0000

Aleafia Health Launches Sunday Market House of Brands

Aleafia Health Launches Sunday Market House of Brands

“The Sunday Market house of brands has been crafted to provide consumers with a welcoming, authentic experience that showcases the local community and the people that create great cannabis products,” said Tricia Symmes, Aleafia Health’s chief commercial officer. “Our well-earned reputation for product quality and excellence serves as the foundation for the launch of these new highly differentiated brands and an expanding product portfolio.”

  • Nith & Grand: The flagship brand’s namesake is a tribute to our product innovation facility’s home community of Paris, Ont., whose scenic downtown core is centred around the confluence of the Nith and Grand rivers. Featuring hang dried, hand trimmed, small batch dried flower, and premium concentrates, Nith & Grand appeals to cannabis aficionados with discerning tastes. First products launch in Q2 2021.
  • Bogart’s Kitchen: An edible cannabis brand, Bogart’s Kitchen combines extensive R&D and culinary experimentation to provide novice and high frequency cannabis consumers with a craveable experience. It will feature high demand formats including soft chews, along with some novel edibles not yet available in Canada. First products will appear in Q1 2021.
  • Divvy: The friendly, everyday cannabis brand, Divvy will feature affordable, high-quality, dried flower, pre-rolls, vape cartridges and concentrates, including larger format SKUs. First products are expected to appear in Q1 or early Q2 2021.
  • Noon & Night: The trailblazing Noon & Night is a cannabis wellness brand, catering to the growing demand for CBD-dominant products in both traditional CPG and other more innovative formats. It will feature innovative formats that are already an important component of consumers’ everyday wellness routine. First products launching in Q2 2021.

For Investor & Media Relations:

Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.

Aleafia Health owns three significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Published at Thu, 11 Feb 2021 12:50:53 +0000